Antibody therapeutics
Routledge Revivals Series

Coordinators: Harris William J., Adair John R.

Language: English

Approximative price 222.92 €

In Print (Delivery period: 12 days).

Add to cartAdd to cart
Publication date:
· 15.6x23.4 cm · Hardback
A comprehensive evaluation of progress toward using humanized antibodies as a new generation of therapeutics. Humanized antibodies are discussed as case studies, offering an insight into the preclinical and clinical data acquired during the regulatory approval process.

Part 1: Antibodies as Therapeutics

1. Unconjugated Antibodies as Therapeutics

M. Clark

2. Immunotoxins for Treating Cancer and Autoimmune Disease

R.J. Kreitman and I. Pastan

3. Antibodies as Carriers for Drug and Radioisotopes

G. Yarranton

4. Tumor Targeting by Antibody-Drug Conjugates

I. Benhar and I. Pastan

Part 2: Application of Antibody Therapeutics

5. Therapeutic Antibodies in Infectious Disease

W.J. Harris

6. Antibody Therapeutics: Application to Autoimmunity

L. Chatenoud

7. Monoclonal Antibodies in Transplantation

M.-L. Alegre

Part 3: Development of Antibody Therapeutics

8. Regulatory Issues for the Development of Antibody Therapeutics

K.J. Lambert

9. Manufacture of Antibodies by Large Scale Mammalian Cell Culture

D.K. Robinson, V. Yabannavar, and Y. Deo

10. Production of Antibody Domains in Prokaryotes

M. Better and P. Gavit

11. Emerging Production Systems for Antibody Therapeutics

A.J.R. Porter et al.

Part 4: Recombinant Antibodies in the Clinic

12. Development of Zenapax™: A Humanized Anti-Tac Antibody

J. Hakimi et al.

13. Progress with a Reshaped Monoclonal Antibody, RSHZ19, for the Prophylaxis and Treatment of Respiratory Syncytial Virus Infection

S.B. Dillon and T.G. Porter

14. CDP571, An Engineered Antibody to Human Tumor Necrosis Factor

S. Stevens, O. Vetterlein, and M. Sopwith

15. The Therapeutic Potential of a Primatized, Nondepleting Anti-CD4 (IDEC-CE9.1) Monoclonal Antibody in Rheumatoid Arthritis

A.M. Solinger et al.

  • Researchers and clinicians in pharmacology, pharmaceutical science, immunology, biotechnology, molecular biology, and toxicology
  • Developmental and regulatory staff in major pharmaceutical and biotech companies
  • Policy and resource decision makers in hospitals, academic institutions, and regulatory bodies

    • William J. Harris, Ph.D., C.Biol, is Professor of Genetics at the University of Aberdeen, Scotland.

    John R. Adair, Ph.D., is Product Development Manager at Axis Genetics, Plc.